Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 59Myelodysplastic Syndromes 14Leukemia 11Recurrence 5Leukemia, Promyelocytic, Acute 5Congenital Abnormalities 5Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Erythroblastic, Acute 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Megakaryoblastic, Acute 3Neoplasm, Residual 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Sarcoma, Myeloid 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Disease Progression 1Disease 1Blast Crisis 1

Interventions

Cyclophosphamide 220Rituximab 189fludarabine phosphate 169fludarabine 102Peripheral Blood Stem Cell Transplantation 100Mycophenolic Acid 94Whole-Body Irradiation 81Tacrolimus 72Filgrastim 69Cyclosporine 67Lenalidomide 66ibrutinib 63Busulfan 61Melphalan 58Antilymphocyte Serum 57Radiotherapy 52venetoclax 48Etoposide 47obinutuzumab 42Bendamustine Hydrochloride 42Alemtuzumab 41Methotrexate 39ofatumumab 28sargramostim 27Granulocyte Colony-Stimulating Factor 26Cytarabine 26Cord Blood Stem Cell Transplantation 26acalabrutinib 25Stem Cell Transplantation 24Specimen Handling 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × Gemtuzumab × Clear all
NCT00038831 2012-08-01

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

M.D. Anderson Cancer Center

Phase 1/2 Completed
47 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡